Topic:

R&D

Latest Headlines

Latest Headlines

Rho inks a federal bioterror pact with $100M on the line

North Carolina CRO Rho has signed up to help the U.S. government's Biomedical Advanced Research and Development Authority design and conduct clinical trials for treatments that protect against bioterrorism and other public health emergencies, getting in line for as much as $100 million over 5 years.

Tomorrow's cardio blockbusters: Inside 'the next big leap' in controlling cholesterol

Thanks to genomic sequencing, some heart-healthy mutants and billions of dollars spent on R&D, rival drug developers are bearing down on a promising new way of treating the scourge of high cholesterol. And with the first FDA applications likely coming in the next year, the nascent field's trailblazers are vying for the top spot with blockbuster aspirations.

On the ropes, Novartis' cardiology team declares a blockbuster PhIII knockout

The pharma giant announced that the data monitoring committee has hit the green light for any early close to the pivotal study for its new blood pressure treatment LCZ696 after investigators tracked delays in cardiovascular deaths and fewer hospitalizations resulting from heart failure in comparison to Vasotec, a generic blood pressure medicine that has been around for years.

Illumina CEO sees bioinformatics as key to completing sequencing puzzle

The expansion of whole-genome sequencing into clinical care has intensified discussions about the limitations of the technology. Illumina CEO Jay Flatley this week acknowledged sequencing still has some weaknesses and identified what he sees as the solution--improved bioinformatics.

Ebola still a tough target due to Big Pharma disinterest and few outbreaks

In the nearly 40 years since scientists first nailed down the Ebola virus, drug researchers have yet to commercialize an effective therapy for the deadly disease, a problem made worse by a lack of commercial promise and the relative rarity of outbreaks.

OrbusNeich wraps enrollment in a post-marketing registry for its dual-therapy stent

OrbusNeich said it has wrapped up enrollment in a 1,000 patient post-marketing registry to evaluate its innovative Combo dual-therapy stent in real-world conditions over the next few years.

Busy week at Intel bolsters its presence in life sciences

Falling sales of personal computers have chipped away at one of the cornerstones of Intel's business over the past few years. The chipmaker has responded by diversifying and this week made three such moves, each of which has implications for the life sciences sector.

Finding: 2 biomarkers for head and neck cancer can help predict radiation therapy resistance

International researchers led by Michigan's Beaumont Health System discovered two biomarkers that helped predict resistance to radiation therapy for patient's with squamous cell cancer of the head and neck.

Covance dials up its biologics offerings, adding 100 new jobs

Global CRO Covance is expanding its heft in biologics development, plotting to double its capacity over the next 5 years.

U.K. team scores with blood test that might spot children likely to become obese

U.K. researchers have made advances developing a blood test that could screen for patients who have a genetic predisposition to obesity. Their work, published in the journal Diabetes, involves a team from the University of Southampton, University of Exeter Medical School and elsewhere.